Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium longum NCC3001
- Development stage
- Unknown
- Lead developer
- Nestlé
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum NCC3001 is a specific probiotic strain from the Nestlé Culture Collection, primarily investigated for its psychotropic properties and effects on the gut-brain axis. It is classified as a live biotherapeutic product and has been evaluated in clinical trials for its ability to reduce depression scores and improve quality of life in patients with Irritable Bowel Syndrome (IBS). Mechanistically, NCC3001 is thought to communicate with the central nervous system via the vagus nerve and by modulating the excitability of enteric sensory neurons. Clinical studies have also explored its potential in managing skin sensitivity and perinatal mood disturbances, although results in the latter have been mixed. Functional magnetic resonance imaging (fMRI) studies have demonstrated that the strain can reduce brain responses to negative emotional stimuli in the amygdala and fronto-limbic regions.
- Brand names
- Calming CareCovetrus Behavior PowderCalming Care Feline Probiotic Supplement
- Other names
- B. longum NCC3001
02
Targets
HCN (HCN channel family)KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)
Beyond the preview
Go deeper on Bifidobacterium longum NCC3001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium longum NCC3001.